* This study will follow the CONSORT guideline as a guide for conducting a clinical trial.
* The sample size was calculated to detect differences in the mean variation in the GAD-7 score (difference between the initial GAD-7 and the final GAD-7) between the Digital Intervention and Control Groups, with a difference of 5 points as relevant for the study. For this, the PSS Health tool version 0.1.6 was used. Considering a power of 80%, a significance level of 5% and a standard deviation of 6 points, the total sample size was 46 subjects, 23 in each group. Adding 30% for possible losses and refusals, the sample size should be 60 (30 in each group).
* Statistical analysis will be performed using descriptive statistics (mean, mode, median, standard deviation, frequencies and percentages). Student's t test will be used to compare means of independent variables. In the conclusions of the statistical tests, a significance level of 5% will be used, that is, whenever p \< 0.05 there is evidence of statistical significance.
* The analyzes are going to use intention-to-treat model, preserving the benefit of randomization and avoiding biases due to exclusion and/or loss of patients during the research.
* The digital interventions will consist of two parts:
A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available free of charge for the patient to watch on Artmed's "+PSI" app, available on both the Apple Store and Google Play. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.
B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on Artmed's +PSI mobile application and will be used to guide clinical management.
* The usual treatment will be standardized as follows:
* Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.
* The patient will receive only clinical, not psychotherapeutic treatment.
* The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.
* The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil.
* The clinician may also opt for some other class of medication associated with the use of fluoxetine, such as benzodiazepines, for example, which must be duly recorded in the database (drug, dose, time of use). If the patient does not have an indication for the use of fluoxetine or does not tolerate its use, he will be excluded from the study and referred to the health unit in his region to evaluate other therapeutic possibilities.
* The follow-up of patients during the research protocol will occur biweekly, online. The videocalls will not be recorded. The duration of the study will be 12 weeks; each patient will have 6 consultations with their clinician.
* Always at the first appointment, the professional will indicate to the patient to download the application on his device (mobile or tablet) and will help him with technical questions. In the intervention group, the patient will leave the consultation with the indication and combination of homework. A video will be indicated to be watched before the next appointment, which will be discussed with the psychiatrist during the next session, debating the topic and clearing up possible doubts. It will also be arranged with the patient to complete the GAD-7 self-administered questionnaire the day before the next scheduled appointment. The result of this assessment will be shared with the practitioner in the next session, and both will discuss and evaluate the results together. If the patient in the intervention group has not seen the video or completed the scale as instructed before the scheduled time, the psychiatrist will do these activities with the patient during consultation time to ensure that he or she has exposure to the intervention.
* Always at the first appointment, the professional will indicate to the patient to download the application on his device (mobile or tablet) and will help him with technical questions. In the intervention group, the patient will leave the consultation with the indication and combination of homework. A video will be indicated to be watched before the next appointment, which will be discussed with the psychiatrist during the next session, debating the topic and clearing up possible doubts. It will also be arranged with the patient to complete the GAD-7 self-administered questionnaire the day before the next scheduled appointment. The result of this assessment will be shared with the practitioner in the next session, and both will discuss and evaluate the results together. If the patient in the intervention group has not seen the video or completed the scale as instructed before the scheduled time, the psychiatrist will do these activities with the patient during consultation time to ensure that he or she has exposure to the intervention.
* Between appointments 3 and 4, patients from both groups will be contacted by one of the blinded evaluators to perform the HAM-A. The purpose of applying this scale in the middle of the study is to assess whether there is a difference in response time between the digital intervention group and the control group.
* Patients will be re-contacted at 3 and 6 months after the end of the survey to complete the GAD-7 and HAM-A scales again, to assess long-term response maintenance and adherence to treatment.
* The Net Promoter scale will be used at the endpoint of the study to assess whether there was a difference in satisfaction with the received treatment between the control and intervention groups.
* As the investigators are going to use a digital tool as an adjunct to the treatment and as the clinician also needs to guide the patient during this intervention and discuss with him about the content of the videos and the results of the scales, there is no possibility of blinding these parts, however, the research group opted for blind the evaluator who will carry out the baseline, mid-term and end-of-study evaluations. The study coordinator will talk to each patient to advise them not to reveal which group they participated during the interview with the blinded evaluator.
* The investigators will also control by sex, age, socioeconomic class to understand whether digital tools can have a different impact on each group. The evaluation of the impact of psychiatric comorbidities will also be evaluated, analyzing them as confounders (presence of associated depression, for example).
* Adherence to the medication prescription will be controlled by counting pills at each visit together with the patient, to avoid confusion bias regarding the use or not of the medication correctly and the improvement of the patient. At each appointment, the patient will be guided by the attending physician to separate the exact number of pills until the date of the next appointment, when the number of remaining pills will be checked again, and the data duly recorded in the database.
* The research group will be composed of 12 members, duly trained for their distinct functions.
* After the selection of the team of professionals who will collaborate with the project, an online course will be given by the project coordinator with all members to explain the research protocol and training of all stages of the project, as well as regarding the evaluation instruments that will be used.
* During the entire course of the research, the assistant clinician will be aware of risks that patients may present during the study, such as suicide risk, for example. When such a situation is identified, the participant will be automatically disconnected from the study and will be referred to specific treatment for his/her condition (in case of suicide risk, the standard measures for this psychiatric emergency will be carried out and the patient will be referred to the nearest psychiatric emergency).
* The prescribed medication will be sent by email to the patient through the system for special prescriptions of the Regional Council of Medicine (CREMERS) and he will look for a Primary Care Center to take the medication. At the endpoint of the study, all patients will be referred to follow treatment in the basic health network closest to their residence, also considering that the medication used is already the medication that is available free of charge in Brazil's health system.
* The database will use RedCap resources, to which all members of this study will have access, always taking into account the necessary ethical precautions.
* All data added to the database will be reviewed by the research assistants daily. Any inconsistency will be immediately reported to the research coordinator.
* All participants will be invited to read, understand the research objectives, through the informed consent form before participating in the study. There is the possibility for the participant to withdraw from the study at any time.
* All data will be kept in a safe place by those responsible for the project, guaranteeing the privacy rights of the interviewees. Only team members will have access to and handle the data collected. Items referring to the confidentiality of the information collected will be guaranteed by the non-identification of subjects.
* The investigators expect that intervention group can show a greater clinical improvement in the assessment of the variation of initial and final GAD symptoms (baseline and endpoint delta), evaluated by GAD-7 and HAM-A scales. To be considered relevant in care practice, the expectation is that this improvement has both statistical and clinical significance.
* Another expected result is to find is that control group presents a higher dropout rate than intervention group, considering the hypothesis that the interventions associated with usual care that will be implemented add benefits of therapeutic bond and adherence to treatment. Furthermore, the investigators assume that the intervention group can start the improvement process faster than the control group and that this improvement will be sustained for longer (follow-up period).
